CareDx says publication of ISHLT guidelines support cardiothoracic portfolio

CareDx announced the publication of new guidelines by the International Society for Heart and Lung Transplantation, or ISHLT, supporting the use of CareDx’s non-invasive molecular surveillance portfolio. The new ISHLT guidelines support the use of CareDx’s cardiothoracic portfolio, AlloMap Heart, AlloSure Heart, and HeartCare. Specifically, the guidelines: support the earlier use of AlloMap Heart starting at two months to five years post-transplant versus starting at six months based on strength of clinical studies; support AlloMap gene-expression profiling, or GEP, and donor-derived cell-free DNA, or dd-cfDNA, for routine post-transplant monitoring, which is new in the current guidelines and reflects increased adoption of non-invasive molecular testing in clinical practice. This includes dd-cfDNA which is new in the current guidelines. Support remote use of GEP and dd-cfDNA heart transplant surveillance, as in HeartCare, as it may be used to reduce the need for biopsies and hospital visits, which is new in the current guidelines, and as evidenced during the recent COVID pandemic.